TY - JOUR
T1 - Tiny Actors in the Big Cellular World: Extracellular Vesicles Playing Critical Roles in Cancer
AU - Jurj, Ancuta
AU - Pop-Bica, Cecilia
AU - Slaby, Ondrej
AU - Ştefan, Cristina D.
AU - Cho, William C.
AU - Korban, Schuyler S.
AU - Berindan-Neagoe, Ioana
N1 - Funding Information:
This research was funded by H2020-MSCA-RISE-2018 No. 824036/2019?Excellence in research and development of non-coding RNA DIAGnostics in Oncology? (RNADIAGON), project PNCDI III 2015?2020 titled ?Increasing the performance of scientific research and technology transfer in translational medicine through the formation of a new generation of young researchers??ECHITAS, No. 29PFE/18.10.2018 and Competitiveness Operational Program, 2014?2020, titled ?Clinical and economic impact of personalized targeted anti-microRNA therapies in reconverting lung cancer chemoresistance??CANTEMIR, No. 35/01.09.2016, MySMIS 103375.
PY - 2020/10/17
Y1 - 2020/10/17
N2 - Communications among cells can be achieved either via direct interactions or via secretion of soluble factors. The emergence of extracellular vesicles (EVs) as entities that play key roles in cell-to-cell communication offer opportunities in exploring their features for use in therapeutics; i.e., management and treatment of various pathologies, such as those used for cancer. The potential use of EVs as therapeutic agents is attributed not only for their cell membrane-bound components, but also for their cargos, mostly bioactive molecules, wherein the former regulate interactions with a recipient cell while the latter trigger cellular functions/molecular mechanisms of a recipient cell. In this article, we highlight the involvement of EVs in hallmarks of a cancer cell, particularly focusing on those molecular processes that are influenced by EV cargos. Moreover, we explored the roles of RNA species and proteins carried by EVs in eliciting drug resistance phenotypes. Interestingly, engineered EVs have been investigated and proposed as therapeutic agents in various in vivo and in vitro studies, as well as in several clinical trials.
AB - Communications among cells can be achieved either via direct interactions or via secretion of soluble factors. The emergence of extracellular vesicles (EVs) as entities that play key roles in cell-to-cell communication offer opportunities in exploring their features for use in therapeutics; i.e., management and treatment of various pathologies, such as those used for cancer. The potential use of EVs as therapeutic agents is attributed not only for their cell membrane-bound components, but also for their cargos, mostly bioactive molecules, wherein the former regulate interactions with a recipient cell while the latter trigger cellular functions/molecular mechanisms of a recipient cell. In this article, we highlight the involvement of EVs in hallmarks of a cancer cell, particularly focusing on those molecular processes that are influenced by EV cargos. Moreover, we explored the roles of RNA species and proteins carried by EVs in eliciting drug resistance phenotypes. Interestingly, engineered EVs have been investigated and proposed as therapeutic agents in various in vivo and in vitro studies, as well as in several clinical trials.
KW - Cancer
KW - Cell-to-cell communication
KW - Extracellular vesicles
KW - Therapeutic agents
UR - http://www.scopus.com/inward/record.url?scp=85092652348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092652348&partnerID=8YFLogxK
U2 - 10.3390/ijms21207688
DO - 10.3390/ijms21207688
M3 - Review article
C2 - 33080788
SN - 1661-6596
VL - 21
SP - 1
EP - 27
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 20
M1 - 7688
ER -